HIK Hikma Pharmaceuticals Plc

RNS Number:4855M
Hikma Pharmaceuticals Plc
22 November 2006


Hikma Pharmaceuticals PLC
                         
Renewal of Contract

London, 22 November 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)
announces the renewal of the sales contract with the Department of Veterans
Affairs, an agency of the government of the United States of America, for the
supply of lisinopril.

The renewal represents the exercise of the 4th Option Year for the contract with
a contract period between 21 December 2006 and 20 December 2007. The contract
has been renewed at a slight discount to last year's renewal price. All other
terms and conditions of the contract remain unchanged.

                                    - ENDS -

Enquiries:

Hikma Pharmaceuticals PLC                      +44 20 7399 2670
Susan Ringdal, Investor Relations Director

Brunswick Group LLP                            +44 20 7404 5959
Jon Coles / Justine McIlroy / Alex Tweed


Notes to Editors

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ("MENA") region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.





                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
CNTEAAFFADKKFAE

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024